Joseph Michael Fitzgerald - 01 Jan 2022 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP & Pres, Cardiology
Signature
/s/ Vance R. Brown, Attorney-in-fact
Issuer symbol
BSX
Transactions as of
01 Jan 2022
Transactions value $
-$301,566
Form type
4
Filing time
03 Jan 2022, 15:49:56 UTC
Previous filing
27 Jul 2021
Next filing
17 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $0 +14K +6.89% $0.00 218K 01 Jan 2022 Direct F1
transaction BSX Common Stock Tax liability -$302K -7.1K -3.26% $42.48 211K 01 Jan 2022 Direct
holding BSX Common Stock 68.3K 01 Jan 2022 By 401(k) F2
holding BSX Common Stock 6.04K 01 Jan 2022 By Children F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Performance Share Units Options Exercise $0 -14K -100% $0.00* 0 01 Jan 2022 Common Stock 14K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.
F2 Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
F3 The reporting person disclaims beneficial ownership of the shares held by his children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or for any other purpose.
F4 Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.